CHIKV-Δ5nsP3 Vaccine Production With Low-MOI Mutation Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for producing Chikungunya virus (CHIKV) vaccine candidates, such as CHIKV-Δ5nsP3, face challenges in maintaining immunogenicity due to mutations that reduce immunogenicity during cell substrate adaptation, necessitating a well-defined process to minimize these mutations while achieving high production titers suitable for industrial application.
Innovation Solution
A process is developed to propagate CHIKV-Δ5nsP3 with controlled parameters, minimizing immunogenicity-reducing mutations, particularly in the E2 protein, using Vero cells with low multiplicity of infection (MOI) and optimized conditions to maintain high production yields and immunogenicity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If CHIKV-Δ5nsP3 is propagated in cell culture to achieve high production titers, then productivity is improved, but immunogenicity-reducing mutations occur during cell substrate adaptation
Solution Approach 1:
The patent applies preliminary action by performing serial passaging of the virus in a controlled manner before production, allowing the virus to adapt to the cell substrate while maintaining immunogenicity. The process includes specific steps of virus isolation, characterization, and stabilization through defined passage numbers in Vero or other suitable cell lines, ensuring the virus strain is optimized for both production and immunogenicity before scale-up
Solution Approach 2:
The patent applies parameter changes by optimizing cell culture conditions including temperature, pH, passage number, and cell density to control virus replication and mutation rates. Specific parameters such as maintaining virus passage number within a defined range (e.g., P1-P10) and controlling multiplicity of infection (MOI) are adjusted to balance production titer with preservation of immunogenicity
2Ease of manufacture
If serial passaging is performed to adapt virus to cell substrate, then ease of manufacture is improved, but mutations reducing immunogenicity accumulate
Solution Approach 1:
The patent applies feedback by implementing monitoring and characterization of the virus strain at defined passage numbers to detect and control mutational drift. The process includes assessing virus properties such as immunogenicity, replication kinetics, and genetic stability to determine when passage should be terminated or when the virus strain requires refreshment from the master seed bank
Solution Approach 2:
The patent performs preliminary characterization and stabilization of the virus strain through controlled serial passaging before actual production. The virus is propagated in Vero or other suitable cell lines under defined conditions for a limited number of passages (P1-P10), and the strain is characterized at each stage to ensure immunogenicity is maintained while achieving adequate adaptation for manufacturing
3Productivity
If high multiplicity of infection is used to increase production yield, then productivity is improved, but frequency of non-immunogenic variants increases
Solution Approach 1:
The patent applies parameter changes by optimizing the multiplicity of infection (MOI) to a specific range (e.g., MOI 0.01-0.1) that balances production yield with immunogenicity maintenance. This controlled MOI prevents excessive viral replication that would lead to mutational accumulation and non-immunogenic variant formation, while still achieving adequate production titers
Data Source
AI summary
The present invention relates to a process for producing an immunogenic live attenuated Chikungunya virus, as well as pharmaceutical compositions comprising the same.